7,716 Shares in Natera, Inc. $NTRA Bought by Bull Harbor Capital LLC

Bull Harbor Capital LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 7,716 shares of the medical research company’s stock, valued at approximately $1,543,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Reflection Asset Management acquired a new position in shares of Natera during the fourth quarter valued at about $29,000. Palladiem LLC acquired a new stake in shares of Natera in the 4th quarter valued at about $31,000. Horizon Investments LLC acquired a new stake in shares of Natera in the 3rd quarter valued at about $32,000. International Assets Investment Management LLC increased its position in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust increased its position in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
• Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Natera in a report on Monday, July 6th. Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Morgan Stanley upped their target price on Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. JPMorgan Chase & Co. increased their target price on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider directly owned 142,295 shares of the company’s stock, valued at $28,984,068.55. The trade was a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 178,862 shares of company stock worth $40,416,335. 5.05% of the stock is currently owned by insiders.

Natera Stock Up 0.6%

Shares of Natera stock opened at $253.82 on Thursday. The company has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The business has a 50 day moving average price of $244.16 and a 200-day moving average price of $221.65.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.